These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31602234)

  • 41. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H; Raza A; Waheed Y; Gill U; Gill ML
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
    Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
    Grasso A; Malfatti F; De Leo P; Martines H; Fabris P; Toscanini F; Anselmo M; Menardo G
    J Hepatol; 2009 Dec; 51(6):984-90. PubMed ID: 19695729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
    Crisan D; Grigorescu MD; Radu C; Suciu A; Grigorescu M
    Indian J Med Res; 2017 Apr; 145(4):543-550. PubMed ID: 28862188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals.
    Nevola R; Rinaldi L; Zeni L; Sasso FC; Pafundi PC; Guerrera B; Marrone A; Giordano M; Adinolfi LE
    JGH Open; 2020 Aug; 4(4):713-721. PubMed ID: 32782961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adiponectin levels and insulin resistance among patients with chronic hepatitis C.
    Carvalho RF; Atta AM; de Oliveira IS; Santos TPS; Santos JPA; Schinoni MI; de Sousa-Atta MLB
    Acta Trop; 2018 Feb; 178():258-263. PubMed ID: 29217381
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
    Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
    Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
    Petta S; Di Marco V; Di Stefano R; Cabibi D; Cammà C; Marchesini G; Craxì A
    J Viral Hepat; 2011 Jul; 18(7):e372-80. PubMed ID: 21692950
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
    Poustchi H; Negro F; Hui J; Cua IH; Brandt LR; Kench JG; George J
    J Hepatol; 2008 Jan; 48(1):28-34. PubMed ID: 17977612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
    Kitson MT; Sarrazin C; Toniutto P; Eslick GD; Roberts SK
    J Hepatol; 2014 Dec; 61(6):1247-52. PubMed ID: 25135863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
    Neumann AU; Bain VG; Yoshida EM; Patel K; Pulkstenis E; Subramanian GM
    Liver Int; 2009 Oct; 29(9):1350-5. PubMed ID: 19291180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of hepatitis C virus infection on insulin resistance in chronic haemodialysis patients.
    Ozdemir A; Yalinbas B; Selamet U; Eres M; Turkmen F; Kumbasar F; Murat B; Keskin AT; Barut Y
    Yonsei Med J; 2007 Apr; 48(2):274-80. PubMed ID: 17461527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
    Iwane S; Mizuta T; Kawaguchi Y; Takahashi H; Oza N; Oeda S; Nakashita S; Kuwashiro T; Otsuka T; Kawazoe S; Eguchi Y; Anzai K; Ozaki I; Fujimoto K
    Intern Med; 2015; 54(24):3113-9. PubMed ID: 26666596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
    Saad Y; Ahmed A; Saleh DA; Doss W
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.
    Kawaguchi T; Ide T; Taniguchi E; Hirano E; Itou M; Sumie S; Nagao Y; Yanagimoto C; Hanada S; Koga H; Sata M
    Am J Gastroenterol; 2007 Mar; 102(3):570-6. PubMed ID: 17222321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.
    Yee BE; Nguyen NH; Zhang B; Lin D; Vutien P; Wong CR; Lutchman GA; Nguyen MH
    BMJ Open Gastroenterol; 2015; 2(1):e000049. PubMed ID: 26462288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.